1
|
Cytoprotective Activity of Polyamines Is Associated with the Alternative Splicing of RAD51A Pre-mRNA in Normal Human CD4 + T Lymphocytes. Int J Mol Sci 2022; 23:ijms23031863. [PMID: 35163785 PMCID: PMC8837172 DOI: 10.3390/ijms23031863] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Revised: 02/03/2022] [Accepted: 02/05/2022] [Indexed: 02/04/2023] Open
Abstract
Physiological polyamines are ubiquitous polycations with pleiotropic biochemical activities, including regulation of gene expression and cell proliferation as well as modulation of cell signaling. They can also decrease DNA damage and promote cell survival. In the present study, we demonstrated that polyamines have cytoprotective effects on normal human CD4+ T lymphocytes but not on cancer Jurkat or K562 cells. Pretreatment of lymphocytes with polyamines resulted in a significant reduction in cells with DNA damage induced by doxorubicin, cisplatin, or irinotecan, leading to an increase in cell survival and viability. The induction of RAD51A expression was in response to DNA damage in both cancer and normal cells. However, in normal cells, putrescin pretreatment resulted in alternative splicing of RAD51A and the switch of the predominant expression from the splice variant with the deletion of exon 4 to the full-length variant. Induction of RAD51A alternative splicing by splice-switching oligonucleotides resulted in a decrease in DNA damage and cell protection against cisplatin-induced apoptosis. The results of this study suggest that the cytoprotective activity of polyamines is associated with the alternative splicing of RAD51A pre-mRNA in normal human CD4+ T lymphocytes. The difference in the sensitivity of normal and cancer cells to polyamines may become the basis for the use of these compounds to protect normal lymphocytes during lymphoblastic chemotherapy.
Collapse
|
2
|
Teixidó C, Giménez-Capitán A, Molina-Vila MÁ, Peg V, Karachaliou N, Rodríguez-Capote A, Castellví J, Rosell R. RNA Analysis as a Tool to Determine Clinically Relevant Gene Fusions and Splice Variants. Arch Pathol Lab Med 2019; 142:474-479. [PMID: 29565207 DOI: 10.5858/arpa.2017-0134-ra] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
CONTEXT - Technologic advances have contributed to the increasing relevance of RNA analysis in clinical oncology practice. The different genetic aberrations that can be screened with RNA include gene fusions and splice variants. Validated methods of identifying these alterations include fluorescence in situ hybridization, immunohistochemistry, reverse transcription-polymerase chain reaction, and next-generation sequencing, which can provide physicians valuable information on disease and treatment of cancer patients. OBJECTIVE - To discuss the standard techniques available and new approaches for the identification of gene fusions and splice variants in cancer, focusing on RNA analysis and how analytic methods have evolved in both tissue and liquid biopsies. DATA SOURCES - This is a narrative review based on PubMed searches and the authors' own experiences. CONCLUSIONS - Reliable RNA-based testing in tissue and liquid biopsies can inform the diagnostic process and guide physicians toward the best treatment options. Next-generation sequencing methodologies permit simultaneous assessment of molecular alterations and increase the number of treatment options available for cancer patients.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Rafael Rosell
- From the Department of Pathology, Hospital Clínic, Barcelona, Spain (Dr Teixidó); Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain (Dr Teixidó); Pangaea Oncology, Oncology Laboratory, Dexeus University Hospital - Quirónsalud Group, Barcelona, Spain (Ms Giménez-Capitán and Drs Molina-Vila, Peg, Karachaliou, Castellví, and Rosell); the Department of Pathology, Hospital Universitario Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain (Drs Peg and Castellví); Morphological Sciences Department, Universitat Autònoma de Barcelona, Barcelona, Spain (Drs Peg and Castellví); Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor and Quirónsalud Group, Barcelona, Spain (Drs Karachaliou and Rosell); the Department of Medical Oncology, Canarias University Hospital, San Cristóbal de La Laguna, Tenerife, Spain (Dr Rodríguez-Capote); and Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain (Dr Rosell)
| |
Collapse
|
3
|
Song X, Tang T, Li C, Liu X, Zhou L. CBX8 and CD96 Are Important Prognostic Biomarkers of Colorectal Cancer. Med Sci Monit 2018; 24:7820-7827. [PMID: 30383736 PMCID: PMC6225733 DOI: 10.12659/msm.908656] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Colorectal cancer (CRC) is one of the most common malignancies worldwide, with high morbidity and mortality rates. The purpose of this study was to identify potential biomarkers in the progression of CRC. MATERIAL AND METHODS Gene and isoform expression datasets of CRC was downloaded from The Cancer Genome Atlas (TCGA). EBSeq of R was used for the normalization of gene and isoform expression, as well as the identification of differential expression genes (DEGs) and isoforms (DEIs) of CRC samples compared with normal samples. The enriched functions of DEGs and DEIs were obtained based on the Database for Annotation, Visualization and Integrated Discovery (DAVID). An independent dataset, GSE38832, was downloaded from the Gene Expression Omnibus (GEO) database for survival analysis of genes with sustained decreased/increased expression values at both gene and isoform levels with the development of CRC. RESULTS A total of 2301 genes and 4241 isoforms were found to be significantly differentially expressed in stage I-IV CRC samples. They are closely associated with muscle or cell system activity. Sixteen genes were screened out with sustained decreased/increased expression values at both gene and isoform levels with the development of CRC. Aberrant CBX8 and CD96 expressions were found to be significantly associated with CRC survival. CONCLUSIONS Through combined analysis of gene and isoform expression profiles, we identified several potential biomarkers that may play an important role in the development of CRC and could be helpful in its early diagnosis and treatment.
Collapse
Affiliation(s)
- Xin Song
- Department of General Surgery, China-Japan Friendship Hospital, Beijing, China (mainland)
| | - Tao Tang
- Department of General Surgery, China-Japan Friendship Hospital, Beijing, China (mainland)
| | - Chaofeng Li
- Department of General Surgery, China-Japan Friendship Hospital, Beijing, China (mainland)
| | - Xin Liu
- Department of General Surgery, China-Japan Friendship Hospital, Beijing, China (mainland)
| | - Lei Zhou
- Department of General Surgery, China-Japan Friendship Hospital, Beijing, China (mainland)
| |
Collapse
|
4
|
Hoff AM, Johannessen B, Alagaratnam S, Zhao S, Nome T, Løvf M, Bakken AC, Hektoen M, Sveen A, Lothe RA, Skotheim RI. Novel RNA variants in colorectal cancers. Oncotarget 2017; 6:36587-602. [PMID: 26474385 PMCID: PMC4742197 DOI: 10.18632/oncotarget.5500] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2015] [Accepted: 09/30/2015] [Indexed: 01/03/2023] Open
Abstract
With an annual estimated incidence of 1.4 million, and a five-year survival rate of 60%, colorectal cancer (CRC) is a major clinical burden. To identify novel RNA variants in CRC, we analyzed exon-level microarray expression data from a cohort of 202 CRCs. We nominated 25 genes with increased expression of their 3′ parts in at least one cancer sample each. To efficiently investigate underlying transcript structures, we developed an approach using rapid amplification of cDNA ends followed by high throughput sequencing (RACE-seq). RACE products from the targeted genes in 23 CRC samples were pooled together and sequenced. We identified VWA2-TCF7L2, DHX35-BPIFA2 and CASZ1-MASP2 as private fusion events, and novel transcript structures for 17 of the 23 other candidate genes. The high-throughput approach facilitated identification of CRC specific RNA variants. These include a recurrent read-through fusion transcript between KLK8 and KLK7, and a splice variant of S100A2. Both of these were overrepresented in CRC tissue and cell lines from external RNA-seq datasets.
Collapse
Affiliation(s)
- Andreas M Hoff
- Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Norwegian Radium Hospital, Oslo, Norway.,KG Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.,Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway
| | - Bjarne Johannessen
- Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Norwegian Radium Hospital, Oslo, Norway.,KG Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.,Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway
| | - Sharmini Alagaratnam
- Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Norwegian Radium Hospital, Oslo, Norway.,KG Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.,Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway
| | - Sen Zhao
- Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Norwegian Radium Hospital, Oslo, Norway.,KG Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.,Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway
| | - Torfinn Nome
- Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Norwegian Radium Hospital, Oslo, Norway.,KG Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.,Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway
| | - Marthe Løvf
- Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Norwegian Radium Hospital, Oslo, Norway.,KG Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.,Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway
| | - Anne C Bakken
- Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Norwegian Radium Hospital, Oslo, Norway.,KG Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.,Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway
| | - Merete Hektoen
- Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Norwegian Radium Hospital, Oslo, Norway.,KG Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.,Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway
| | - Anita Sveen
- Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Norwegian Radium Hospital, Oslo, Norway.,KG Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.,Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway
| | - Ragnhild A Lothe
- Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Norwegian Radium Hospital, Oslo, Norway.,KG Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.,Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway
| | - Rolf I Skotheim
- Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Norwegian Radium Hospital, Oslo, Norway.,KG Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.,Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway
| |
Collapse
|
5
|
High expression of Rad51c predicts poor prognostic outcome and induces cell resistance to cisplatin and radiation in non-small cell lung cancer. Tumour Biol 2016; 37:13489-13498. [PMID: 27465554 DOI: 10.1007/s13277-016-5192-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2016] [Accepted: 07/13/2016] [Indexed: 02/06/2023] Open
Abstract
Rad51c is critical for homologous recombination repair and genomic stability and may play roles in tumorigenesis and cancer therapy. We investigated the expression level and clinical significance of Rad51c in non-small cell lung cancer (NSCLC) and determined the effect of Rad51c on NSCLC cell chemosensitivity and radiosensitivity. Rad51c expression was detected using immunohistochemistry and was higher in NSCLC patient samples than in adjacent normal tissues. Kaplan-Meier analysis revealed that high Rad51c expression was an independent predictor of short overall survival (OS) and disease-free survival (DFS) in NSCLC patients receiving chemotherapy and/or radiotherapy. Furthermore, Rad51c knockdown increased the killing effect of ionizing radiation (IR) and enhanced cisplatin-induced apoptotic cells in NSCLC cells by disrupting the repair of cisplatin- and IR-induced DNA damage. In addition, ectopic expression of Rad51c dramatically enhanced NSCLC cell resistance to cisplatin and radiotherapy. These findings suggest that increased expression of Rad51c may confer resistance to chemotherapy and/or radiotherapy of NSCLC, and also be an independent prognostic factor for patient outcome. Therefore, targeting Rad51c may represent an improved therapeutic strategy for NSCLC patients with locally advanced disease.
Collapse
|
6
|
Shen Y, Lee YH, Panneerselvam J, Zhang J, Loo LWM, Fei P. Mutated Fanconi anemia pathway in non-Fanconi anemia cancers. Oncotarget 2016; 6:20396-403. [PMID: 26015400 PMCID: PMC4653013 DOI: 10.18632/oncotarget.4056] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2015] [Accepted: 04/22/2015] [Indexed: 01/01/2023] Open
Abstract
An extremely high cancer incidence and the hypersensitivity to DNA crosslinking agents associated with Fanconi Anemia (FA) have marked it to be a unique genetic model system to study human cancer etiology and treatment, which has emerged an intense area of investigation in cancer research. However, there is limited information about the relationship between the mutated FA pathway and the cancer development or/and treatment in patients without FA. Here we analyzed the mutation rates of the seventeen FA genes in 68 DNA sequence datasets. We found that the FA pathway is frequently mutated across a variety of human cancers, with a rate mostly in the range of 15 to 35 % in human lung, brain, bladder, ovarian, breast cancers, or others. Furthermore, we found a statistically significant correlation (p < 0.05) between the mutated FA pathway and the development of human bladder cancer that we only further analyzed. Together, our study demonstrates a previously unknown fact that the mutated FA pathway frequently occurs during the development of non-FA human cancers, holding profound implications directly in advancing our understanding of human tumorigenesis as well as tumor sensitivity/resistance to crosslinking drug-relevant chemotherapy.
Collapse
Affiliation(s)
- Yihang Shen
- Program of Cancer Biology, University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI, USA
| | - Yuan-Hao Lee
- Program of Cancer Biology, University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI, USA
| | - Jayabal Panneerselvam
- Program of Cancer Biology, University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI, USA
| | - Jun Zhang
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | - Lenora W M Loo
- Program of Epidemiology, University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI, USA
| | - Peiwen Fei
- Program of Cancer Biology, University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI, USA
| |
Collapse
|
7
|
Kalvala A, Gao L, Aguila B, Dotts K, Rahman M, Nana-Sinkam SP, Zhou X, Wang QE, Amann J, Otterson GA, Villalona-Calero MA, Duan W. Rad51C-ATXN7 fusion gene expression in colorectal tumors. Mol Cancer 2016; 15:47. [PMID: 27296891 PMCID: PMC4906819 DOI: 10.1186/s12943-016-0527-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2015] [Accepted: 05/20/2016] [Indexed: 11/10/2022] Open
Abstract
Background Fusion proteins have unique oncogenic properties and their identification can be useful either as diagnostic or therapeutic targets. Next generation sequencing data have previously shown a fusion gene formed between Rad51C and ATXN7 genes in the MCF7 breast cancer cell line. However, the existence of this fusion gene in colorectal patient tumor tissues is largely still unknown. Methods We evaluated for the presence of Rad51C-ATXN7 fusion gene in colorectal tumors and cells by RT-PCR, PCR, Topo TA cloning, Real time PCR, immunoprecipitation and immunoblotting techniques. Results We identified two forms of fusion mRNAs between Rad51C and ATXN7 in the colorectal tumors, including a Variant 1 (fusion transcript between Rad51C exons 1–7 and ATXN7 exons 6–13), and a Variant 2 (between Rad51C exons 1–6 and ATXN7 exons 6–13). In silico analysis showed that the Variant 1 produces a truncated protein, whereas the Variant 2 was predicted to produce a fusion protein with molecular weight of 110 KDa. Immunoprecipitation and Western blot analysis further showed a 110 KDa protein in colorectal tumors. 5-Azacytidine treatment of LS-174 T cells caused a 3.51-fold increase in expression of the fusion gene (Variant 2) as compared to no treatment controls evaluated by real time PCR. Conclusion In conclusion we found a fusion gene between DNA repair gene Rad51C and neuro-cerebral ataxia Ataxin-7 gene in colorectal tumors. The in-frame fusion transcript of Variant 2 results in a fusion protein with molecular weight of 110 KDa. In addition, we found that expression of fusion gene is associated with functional impairment of Fanconi Anemia (FA) DNA repair pathway in colorectal tumors. The expression of Rad51C-ATXN7 in tumors warrants further investigation, as it suggests the potential of the fusion gene in treatment and predictive value in colorectal cancers. Electronic supplementary material The online version of this article (doi:10.1186/s12943-016-0527-1) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Arjun Kalvala
- Comprehensive Cancer Center, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA
| | - Li Gao
- Comprehensive Cancer Center, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA
| | - Brittany Aguila
- Comprehensive Cancer Center, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA
| | - Kathleen Dotts
- Comprehensive Cancer Center, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA
| | - Mohammad Rahman
- Comprehensive Cancer Center, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA
| | - Serge P Nana-Sinkam
- Comprehensive Cancer Center, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA.,Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA
| | - Xiaoping Zhou
- Department of Pathology, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA
| | - Qi-En Wang
- Department of Radiology, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA
| | - Joseph Amann
- Comprehensive Cancer Center, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA.,Division of Medical Oncology Department of Internal Medicine, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA
| | - Gregory A Otterson
- Comprehensive Cancer Center, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA.,Division of Medical Oncology Department of Internal Medicine, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA
| | - Miguel A Villalona-Calero
- Comprehensive Cancer Center, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA. .,Division of Medical Oncology Department of Internal Medicine, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA. .,Department of Pharmacology, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA.
| | - Wenrui Duan
- Comprehensive Cancer Center, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA. .,Division of Medical Oncology Department of Internal Medicine, the Ohio State University College of Medicine and Public Health, Columbus, Ohio, 43210, USA.
| |
Collapse
|